该股最近90天内共有3家机构给出评级，买入评级3家。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资金流 向。 注：主力资金为特大单成交，游资为大单成交，散户为中小单成交 该股主要指标及行业内排名如下： 祥生医疗2025年三季报显示，前三季度公司主营收入3.43亿元，同比下降5.27%；归母净利润9392.05万 元，同比下降4.56%；扣非净利润8696.66万元，同比下降2.69%；其中2025年第三季度，公司单季度主 营收入1.07亿元，同比下降6.68%；单季度归母净利润2422.41万元，同比上升41.95%；单季度扣非净利 润2314.06万元，同比上升53.63%；负债率11.24%，投资收益301.23万元，财务费用-1652.62万元，毛利 率59.82%。祥生医疗（688358） ...

融券方面，港通医疗2月4日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量0.00股，融券余额0.00元，超过近一年60%分位水平，处于较高位。 资料显示，四川港通医疗设备集团股份有限公司位于四川省成都市简阳市凯力威工业大道南段356号， 成立日期1998年1月13日，上市日期2023年7月25日，公司主营业务涉及为医疗机构提供以医用气体系统 及医院洁净手术部为核心的医疗专业工程整体方案。主营业务收入构成为：医用洁净装备及系统 55.69%，医用气体装备及系统37.30%，医疗设备及其他产品销售4.06%，运维服务2.81%，其他(补 充)0.14%。 来源：新浪证券-红岸工作室 2月4日，港通医疗涨0.67%，成交额7357.36万元。两融数据显示，当日港通医疗获融资买入额513.41万 元，融资偿还700.28万元，融资净买入-186.87万元。截至2月4日，港通医疗融资融券余额合计1.47亿 元。 融资方面，港通医疗当日融资买入513.41万元。当前融资余额1.47亿元，占流通市值的8.29%，融资余 额超过近一年90%分位水平，处于高位。 截至1月30日，港通医 ...

分组1 - Steris reported quarterly earnings of $2.53 per share, matching the Zacks Consensus Estimate, and showing an increase from $2.32 per share a year ago, with an earnings surprise of -0.10% [1] - The company achieved revenues of $1.5 billion for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 1.08%, and up from $1.37 billion year-over-year [2] - Steris has surpassed consensus EPS estimates three times over the last four quarters, indicating a positive trend in earnings performance [2] 分组2 - The stock has gained approximately 3.2% since the beginning of the year, outperforming the S&P 500's gain of 1.1% [3] - The current consensus EPS estimate for the upcoming quarter is $2.88 on revenues of $1.6 billion, and for the current fiscal year, it is $10.23 on revenues of $5.93 billion [7] - The Medical - Instruments industry, to which Steris belongs, is currently ranked in the top 38% of over 250 Zacks industries, suggesting a favorable outlook for the sector [8]

Accuray (NasdaqGS:ARAY) Q2 2026 Earnings call February 04, 2026 04:30 PM ET Company ParticipantsAli Pervaiz - SVP and CFOSteve La Neve - CEOSteve Monroe - VP of Financial Planning and AnalysisConference Call ParticipantsMarie Thibault - Managing Director and Medical Technology and Digital Health AnalystYoung Li - SVP and Equity Research AnalystOperatorGood afternoon and welcome to Accuray's conference call to review financial results for the second quarter of fiscal year 2026, which ended December 31st of 2 ...

Accuray (NasdaqGS:ARAY) Q2 2026 Earnings call February 04, 2026 04:30 PM ET Speaker0Good afternoon and welcome to Accuray's conference call to review financial results for the second quarter of fiscal year 2026, which ended December 31st of 2025. All participants will be in a listen-only mode. Should you need assistance, please signal conference specialists by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press s ...

Group 1 - The State Administration for Market Regulation has released 32 national metrology technical specifications, covering various fields including intelligent connected vehicles, health, and smart meters [1][2] - The "Automatic Parking Performance Measurement Specification for Intelligent Connected Vehicles" is the first professional measurement specification for automatic parking performance in China, filling a technical gap in the industry and promoting the development and upgrade of automatic parking technology [1] - In the health sector, the "Electrocardiogram Machine Verification Procedure" standardizes the measurement verification framework for both analog and digital ECG machines, ensuring accurate diagnostic data for critical health assessments [1] Group 2 - The "Verification Procedure for Installed AC Energy Meters" consolidates five previous measurement specifications into one, enhancing technical requirements and operational feasibility, while addressing public concerns regarding measurement accuracy [2] - New specifications also include guidelines for determining verification cycles for measuring instruments and performance evaluation for instruments with additional functions, laying the groundwork for upgrading metrology technical standards [2]

Group 1 - The State Administration for Market Regulation has released 32 national metrology technical specifications, covering various fields including intelligent connected vehicles, health, and smart meters [1][2] - The "Measurement Testing Specification for Automatic Parking Performance of Intelligent Connected Vehicles" is the first professional metrology testing standard for automatic parking performance in China, filling a technical gap in the industry [1] - The specification aims to unify and compare measurement testing results for key parameters in automatic parking technology, promoting research and development while ensuring safety for drivers and passengers [1] Group 2 - In the field of health, the "Electrocardiogram Machine Testing Regulations" standardizes the metrology testing framework for both analog and digital ECG machines, ensuring accurate diagnostic data for heart-related conditions [1] - The revised "Testing Regulations for Installed AC Energy Meters" consolidates five previous metrology technical specifications, enhancing technical requirements and operational feasibility, while addressing public concerns regarding measurement accuracy [2] - Additional general metrology technical specifications have been released, including principles for determining calibration cycles and performance evaluation guidelines for measuring instruments, laying the foundation for upgrading metrology standards [2]

Core Viewpoint - Shanghai United Imaging Healthcare Co., Ltd. (United Imaging) has rapidly developed into a leading player in the high-end medical equipment sector, achieving a market value exceeding 100 billion yuan within just 15 years through a commitment to independent research and development and a comprehensive global strategy [6][7][8]. Group 1: Company Overview - United Imaging has established a comprehensive industrial matrix covering medical imaging, radiotherapy products, life science instruments, medical robots, smart wearable devices, and medical chips, achieving full-chain coverage from core technology to key components [6][8]. - The company has products installed in over 2,700 tertiary hospitals across China and has expanded its presence to more than 90 countries and regions, including the United States, Germany, France, India, and South Korea [6][11]. Group 2: Development Strategy - The company adheres to three core principles: full-line independent research and development, mastery of all core technologies, and alignment with international top standards, which have guided its development for over a decade [8][9]. - United Imaging has launched over 260 products, including advanced systems like the 5.0T whole-body MRI and the first integrated CT linear accelerator, setting multiple industry benchmarks [10]. Group 3: Global Expansion - United Imaging has adopted a "high-profile" global strategy, focusing on high-end self-researched innovative equipment to penetrate key markets and establish brand recognition in developed countries [12][13]. - The company has successfully entered the U.S. market, with over 400 units installed across more than 70% of state-level administrative regions, including over 150 PET/CT devices [13]. Group 4: Future Goals - The company aims to leverage national policy support to enhance its role as a "chain master" in the high-end medical equipment industry, focusing on innovation and integration of technology, industry, finance, and talent [15][16]. - United Imaging plans to build a multi-layered, international talent pool by 2030 and continue to deepen its international strategy, targeting Southeast Asia, Europe, India, and the U.S. for market expansion [17][18].

Core Viewpoint - The company, 瑞迈特, is adjusting its investment structure for certain fundraising projects and extending the timelines for project completion, which aims to enhance the efficiency of fund utilization and optimize resource allocation [2][3]. Group 1: Company Performance - As of February 4, 2026, 瑞迈特's stock closed at 83.65 yuan, with an increase of 1.14% and a turnover rate of 1.01%, totaling a trading volume of 7,097 hands and a transaction amount of 58.92 million yuan [1]. - On the same day, the net outflow of main funds was 202.4 thousand yuan, while retail investors saw a net inflow of 176.79 thousand yuan [4]. Group 2: Corporate Announcements - On February 3, 2026, 瑞迈特's board of directors approved adjustments to the internal investment structure of certain fundraising projects, including increasing marketing and research and development investments while reducing expenditures on channel construction and equipment [2][3]. - The expected completion dates for several projects, including the annual production of 300,000 ventilators and 3.5 million sets of accessories, have been postponed to December 31, 2027, while the medical equipment research and development center project has been extended to December 31, 2026 [2][3].

Financial Data and Key Metrics Changes - The company reported revenue of $5.7 billion for Q4 2025, representing a 4.8% organic growth year-over-year, exceeding expectations [14] - For the full year 2025, revenue reached $20.6 billion, with organic growth of 3.5%, ahead of guidance [16] - Adjusted EBIT margin for Q4 was 16.7%, down 200 basis points due to tariff expenses and unfavorable mix [14] - Adjusted EPS for Q4 was $1.44, down 0.7%, but grew 11% when excluding tariff impacts [15] - Free cash flow for Q4 was $916 million, up $105 million year-over-year [15] Business Line Data and Key Metrics Changes - Pharmaceutical Diagnostics saw organic sales growth of 12.7%, driven by global growth in contrast media and pricing execution [20] - Imaging organic revenue grew 5.3% in Q4, with strong performance in EMEA and the US, particularly in nuclear medicine [17] - Advanced Visualization Solutions reported organic revenue growth of 4.2%, supported by new product adoption [18] - Patient Care Solutions experienced a 1.1% decline in organic revenue due to a drop in life support solutions, but EBIT margin improved sequentially [19] Market Data and Key Metrics Changes - Demand in the U.S. and EMEA remained strong, with a record backlog of $21.8 billion, up $2 billion year-over-year [14] - The company secured multiple large agreements, including a significant collaboration with Sutter Health and a multi-year agreement with the Ministry of Health in Indonesia [10][11] Company Strategy and Development Direction - The company is focused on an innovation renaissance, emphasizing integrated solutions for complex and chronic diseases [4] - The strategic framework includes precision care, growth acceleration, and business optimization, with a strong emphasis on the Heartbeat business system to drive productivity and customer experience [11][12] - The planned acquisition of Intelerad is expected to enhance the company's cloud-first imaging ecosystem and drive recurring revenue [5] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to deliver over $500 million in Flyrcado revenue by year-end 2028, viewing it as a billion-dollar opportunity in the long run [10] - The company anticipates organic revenue growth of 3%-4% for 2026, with a cautious outlook on China impacting overall guidance [22][23] - Management highlighted the importance of new product launches and regulatory approvals in driving future growth [30] Other Important Information - The company has made significant investments in innovation, deploying over $1.7 billion in 2025 to strengthen competitiveness [17] - The service business grew mid-single digits in 2025, with expectations for increased capture rates of service agreements due to new product launches [11] Q&A Session Summary Question: Can you provide more color on the 2% order growth and outlook for orders in 2026? - Management noted a robust order backdrop with a book-to-bill ratio of 1.06 times and a record backlog, indicating a solid setup for 2026 [27][28] Question: What is the current state of Flyrcado and its adoption? - Management reported positive feedback from clinicians regarding Flyrcado's image quality and convenience, with consistent delivery rates improving [31][32] Question: How should we think about the potential upside in EPS related to China? - Management took a cautious approach regarding China, anticipating a decline in 2026 but noting improvements in VBP win rates and a robust imaging funnel [40][41] Question: Can you elaborate on the timing of orders and sales for new products? - Management indicated that significant new product launches are on track, with expected contributions primarily in 2027, but some impact anticipated in 2026 [60][61] Question: What are the expectations for pricing in 2026? - Management indicated that while there are no significant price increases expected initially, new products may lead to higher pricing as they are introduced [77]